Karin Badel

Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Steven M. Devine, Neal Flomenberg, David H. Vesole et al. · Journal of Clinical Oncology · 2004 · 415 citations · Full text

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Craig W. Hendrix, Ann C. Collier, Michael M. Lederman et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 362 citations

Cxcr4 Receptor Inhibitor, Medicine, Antiviral Activity +14

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Gary Calandra, John M. McCarty, Joseph P. McGuirk et al. · Bone Marrow Transplantation · 2007 · 277 citations

Hematological Malignancy, Cell Therapy, Compassionate Use Data +9

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist

W. Conrad Liles, Elin Rodger, Hal E. Broxmeyer et al. · Transfusion · 2005 · 230 citations · Full text

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

Michael J. Dugan, Richard T. Maziarz, Auayporn Nademanee et al. · Bone Marrow Transplantation · 2009 · 137 citations

Hematological Malignancy, Medicine, Exploratory Trial +5